SFBC International, Inc. has appointed Jeffrey P. McMullen as chief executive officer replacing Arnold Hantman, who is retiring. The board also has accepted the resignation of Dr. Lisa Krinsky, who served as the company’s president and chairman.

Jack Levine, previously lead director, has been elected chairman of the board of directors. As a result of the departures of Mr. Hantman and Dr. Krinsky from SFBC’s board of directors, the company currently has four independent directors and two management directors. The company is conducting a search for additional directors.

Mr. McMullen has more than 30 years of experience in the drug development industry. He has served as president and chief executive officer of PharmaNet prior to the merger with SFBC and he will continue in that role. Prior to co-founding PharmaNet in 1996, he was a member of the senior management team at Corning Pharmaceutical Services (now Covance) where he spent 13 years in a range of operational, business development and sales and marketing roles, including vice president of corporate business development and business unit head and director of clinical research. Previously, he held positions in clinical, regulatory and drug metabolism, including nine years with Sterling Drug Inc.